Photopheresis Products Market Analysis

Photopheresis Products Market Analysis

Based on product type, the photopheresis products market is segmented into closed system and open system. The closed system segment held the largest revenue size over USD 150 million in 2022 and is estimated to cross USD 240 million by 2032. Closed systems are designed to minimize the risk of contamination during the photopheresis procedure. With closed systems, the patient's blood or blood components remain contained within a closed circuit, reducing the exposure to external contaminants. This helps maintain the sterility and integrity of the blood sample, reducing the risk of infection or other complications.
 

Photopheresis products market is bifurcated based on the application including graft versus host disease (GVHD), autoimmune diseases, cutaneous T-cell lymphoma, and transplant rejections. The graft versus host disease segment is anticipated to grow over USD 170 million by 2032. GVHD is a common complication following allogeneic hematopoietic stem cell transplantation (HSCT), which involves the transplantation of stem cells from a donor to a recipient. The incidence and prevalence of GVHD in HSCT can vary depending on several factors, including the type of transplant, stem cell source (bone marrow, peripheral blood, or cord blood), conditioning regimen, and patient characteristics. It is estimated that acute GVHD occurs in 30% to 50% of allogeneic HSCT cases, while chronic GVHD occurs in approximately 40% to 60% of cases.
 

The photopheresis products market is segmented by end-use into hospitals, ambulatory surgical centres, and others. Hospitals segment accounting for more than 45% market share in 2022 and is estimated to witness over USD 200 million by 2032. Due to the widespread availability of innovative and affordable treatments, factors including the increase in testing and growing preference for treatment at hospitals will fuel market expansion. Hospitals also enable to offer early and precise disease diagnosis and patient treatment.
 

U.S. photopheresis products market accounted for more than USD 95 million in 2022 and will grow momentously more than USD 150 million by 2032. The affordability of photopheresis products among the target population base and ongoing technological developments are primarily responsible for the development of the regional business. Further, the region's high healthcare spending on health care management and rising disposable income will propel the expansion of the North America industry. Also, the substantial presence of well-established market participants and the favourable regulatory environment result in substantial number of product approvals and launches, particularly in the U.S.